Brooklyn Investment Group raised its holdings in AstraZeneca PLC (NASDAQ:AZN - Free Report) by 728.6% in the first quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm owned 14,707 shares of the company's stock after purchasing an additional 12,932 shares during the period. Brooklyn Investment Group's holdings in AstraZeneca were worth $1,081,000 at the end of the most recent quarter.
A number of other institutional investors have also recently bought and sold shares of the business. Summit Securities Group LLC boosted its holdings in AstraZeneca by 2,065.1% in the 1st quarter. Summit Securities Group LLC now owns 12,233 shares of the company's stock valued at $899,000 after purchasing an additional 11,668 shares during the period. Seven Mile Advisory boosted its holdings in AstraZeneca by 11.1% in the 1st quarter. Seven Mile Advisory now owns 4,560 shares of the company's stock valued at $335,000 after purchasing an additional 455 shares during the period. Corient IA LLC bought a new stake in AstraZeneca in the 1st quarter valued at about $514,000. Steward Partners Investment Advisory LLC boosted its holdings in AstraZeneca by 10.9% in the 1st quarter. Steward Partners Investment Advisory LLC now owns 49,954 shares of the company's stock valued at $3,672,000 after purchasing an additional 4,893 shares during the period. Finally, Tyler Stone Wealth Management bought a new stake in AstraZeneca in the 1st quarter valued at about $211,000. Institutional investors own 20.35% of the company's stock.
Analyst Ratings Changes
Separately, Berenberg Bank set a $97.00 price objective on shares of AstraZeneca in a report on Wednesday, July 9th. Four analysts have rated the stock with a Buy rating and one has assigned a Hold rating to the stock. According to MarketBeat, the stock currently has an average rating of "Moderate Buy" and an average target price of $86.00.
Check Out Our Latest Research Report on AZN
AstraZeneca Price Performance
Shares of NASDAQ:AZN traded up $0.51 during midday trading on Friday, hitting $80.97. The stock had a trading volume of 3,603,750 shares, compared to its average volume of 5,263,452. The company's 50-day moving average price is $72.80 and its 200-day moving average price is $72.16. The company has a market capitalization of $251.12 billion, a P/E ratio of 30.44, a price-to-earnings-growth ratio of 1.48 and a beta of 0.36. AstraZeneca PLC has a fifty-two week low of $61.24 and a fifty-two week high of $87.68. The company has a quick ratio of 0.67, a current ratio of 0.86 and a debt-to-equity ratio of 0.55.
AstraZeneca (NASDAQ:AZN - Get Free Report) last released its quarterly earnings data on Tuesday, July 29th. The company reported $1.09 earnings per share (EPS) for the quarter, hitting analysts' consensus estimates of $1.09. The business had revenue of $14.46 billion during the quarter, compared to analysts' expectations of $14.08 billion. AstraZeneca had a net margin of 14.68% and a return on equity of 32.84%. The firm's quarterly revenue was up 16.1% compared to the same quarter last year. During the same period in the prior year, the company earned $1.24 EPS. As a group, equities research analysts predict that AstraZeneca PLC will post 4.51 EPS for the current fiscal year.
AstraZeneca Cuts Dividend
The business also recently disclosed a semi-annual dividend, which will be paid on Monday, September 8th. Investors of record on Friday, August 8th will be given a dividend of $0.505 per share. This represents a yield of 200.0%. The ex-dividend date is Friday, August 8th. AstraZeneca's dividend payout ratio is currently 37.97%.
AstraZeneca Profile
(
Free Report)
AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company's marketed products include Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Lokelma, Roxadustat, Andexxa, Crestor, Seloken, Onglyza, Bydureon, Fasenra, Breztri, Symbicort, Saphnelo, Tezspire, Pulmicort, Bevespi, and Daliresp for cardiovascular, renal, metabolism, and oncology.
Further Reading
Before you consider AstraZeneca, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and AstraZeneca wasn't on the list.
While AstraZeneca currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
MarketBeat All Access